|Bid||9.91 x 1200|
|Ask||10.01 x 800|
|Day's range||9.71 - 10.13|
|52-week range||3.60 - 25.77|
|Beta (3Y monthly)||2.13|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
DBV Technologies S.A. (DBVT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! DBV Technologies S.A. (EPA:DBV) is a stock Read More...
Biopharmaceutical firms Aimmune Therapeutics and DBV Technologies are both competing to develop drugs to treat peanut allergies and get FDA approval first in 2019.
In 2002 Pierre-Henri Benhamou was appointed CEO of DBV Technologies SA (EPA:DBV). This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Next, we’ll Read More...
Allergies are on the rise and researchers are trying new methods to help combat potentially life threatening reactions.